Publisher's Synopsis
This publication provides up-to-date information on the use of the anti-emetic ondansetron, the first 5-HT3 receptor antagonist to be developed and marketed. Leading specialists discuss the physiology of post-chemotherapy emesis, and present the results of clinical studies regarding simplified dosing schedules of ondansetron as well as its superior efficacy compared with other anti-emetic drugs. Further papers are concerned with the methodology of clinical studies including the problem of assessing the patients' quality of life. Finally, the nurse's perspective regarding the management of emesis following chemotherapy is evaluated. In summary, this collection of data shows that ondansetron is an effective and well-tolerated anti-emetic for both adult and paediatric patients receiving emetogenic cancer treatment.
